MOG

Flash News: OKX Wallet Launches 'Base Meme Token Super Season' with a USD46,000 Prize Pool

Retrieved on: 
星期三, 四月 17, 2024
MOG, Social media, Base, AYB, Web3, Comment, FOMO, DEX, CAP, EZ, OKX, Cryptocurrency

SINGAPORE, April 17, 2024 /PRNewswire/ -- OKX , a leading Web3 technology company, has issued updates for April 17, 2024.

Key Points: 
  • SINGAPORE, April 17, 2024 /PRNewswire/ -- OKX , a leading Web3 technology company, has issued updates for April 17, 2024.
  • OKX Wallet today launched its ' Base Meme Token Super Season ' campaign.
  • The campaign, which began today and ends on April 26, gives users who complete social media tasks and trade on OKX's multi-chain, cross-chain DEX aggregator the opportunity to claim a share of a USD46,000 prize pool.
  • More specifically, rewards include a USD5,000 prize pool for users who follow 11 Base memecoin X accounts and the OKX Web3 X account, as well as like, comment and tweet this post .

$MOG Social Media Team Discusses the Power of Memes with Malik Obama

Retrieved on: 
星期一, 十一月 6, 2023
Crypto, Islam, Social media, Serotonin, Attention, OSF, DOGE, Dopamine, Tesla, Atmosphere, Interview, Marketing, Wizard, Culture, Consciousness, SHIB, Spirituality, MOG, Cryptocurrency, Entertainment, Farrokh

Since the days of the Wizard of Menlo Park, this has become increasingly apparent, especially within the realm of cryptocurrency and blockchain technology.

Key Points: 
  • Since the days of the Wizard of Menlo Park, this has become increasingly apparent, especially within the realm of cryptocurrency and blockchain technology.
  • Social media has opened up a new venue for this battle of consciousness through memetic warfare, as tokens such as DOGE, SHIB, PEPE, and now $MOG have seen mass adoption by way of earning their place in the public’s mind.
  • Recently, members of $MOG’s community sat down with Malik Obama , the half-brother of former President Barack Obama, to discuss the role of memes, the power of collective creation, and the stratospheric rise of $MOG over the past few months.
  • Defining what made $MOG special, the host pointed toward the collective efforts of the community of creators: graphic designers, social media influencers, merchandisers, and program developers all working to enable one-another’s creative output.

Kazakhstan-Singapore Business Forum: ONERHT leads investment in Kazakhstan gold mining company

Retrieved on: 
星期一, 五月 22, 2023
LLP, Partnership, Monetary Authority of Singapore, MAS, MOG, Gold, MOU, Mining, Ecosystem, RHT, Uranium mining, Cryptocurrency, Management, Tutoring, Biryuk

- Investment to support the exploration, mining, extraction and refining of gold from Biryuk's mine in Kazakhstan with US$1B potential reserves

Key Points: 
  • - Investment to support the exploration, mining, extraction and refining of gold from Biryuk's mine in Kazakhstan with US$1B potential reserves
    Astana, Kazakhstan, May 22, 2023 - (ACN Newswire) - RHT AlDigi Financial Holdings Pte.
  • Ltd. (RHTAFH) and Biryuk Altyn LLP have signed a Memorandum of Understanding (MOU) to invest in and commercialise Biryuk's gold mine, with support from the ONERHT ecosystem.
  • [L-R]
    RHTAFH is a member of ONERHT, a Singapore-based multidisciplinary professional and specialist services group while Biryuk owns a 56sqkm gold mine, located 600km from Kazakhstan's capital, Astana.
  • The mine holds probable reserves of 50-100 tons of gold with a potential value of US$1 billion.

CHOP Researcher Leads International Panel in Developing First-Ever Clinical Diagnosis Guidelines for MOGAD

Retrieved on: 
星期五, 二月 17, 2023
Consensus, Online, The Lancet, Brain, Spinal cord, Paratriathlon, Confusion, Child, Mayo Clinic, Diagnosis, Clinical professor, Seizure, Division, Weakness, Patient, Hospital, Inflammation, Lancet Neurology, Cuban Neuroscience Center, MOG, DSM-IV codes, MOGAD, Immune system, CHOP, International, Antibody, Disease, Multiple sclerosis, Somnolence, Central nervous system, Neurological disorder, MS, Encephalopathy, Medical imaging, Neurology, MD

PHILADELPHIA, Feb. 17, 2023 /PRNewswire/ -- An international panel led by a pediatric neuroimmune expert and co-director of the Neuroscience Center at Children's Hospital of Philadelphia (CHOP) has established new criteria for properly diagnosing myelin oligodendrocyte glycoprotein antibody-associated diseased (MOGAD), a neurological disorder that causes inflammation and potential damage of the brain, spinal cord and optic nerves. While further validation is needed, these proposed guidelines, recently published in The Lancet Neurology, are the first clinical guidelines for MOGAD and provide an important framework for distinguishing MOGAD from other neurological disorders.

Key Points: 
  • While further validation is needed, these proposed guidelines, recently published in The Lancet Neurology , are the first clinical guidelines for MOGAD and provide an important framework for distinguishing MOGAD from other neurological disorders.
  • MOGAD is a demyelinating disorder of the central nervous system, meaning that damage is being caused to the myelin, or protective covering, of pathways in the brain.
  • To formulate these clinical guidelines for diagnosis, the international team conducted an extensive literature review and structured process and then derived international consensus criteria to aid in the diagnosis of MOGAD.
  • Banwell et al, "Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria."

IN CELEBRATION OF BOB MARLEY'S 78TH BIRTHDAY, THE MARLEY FAMILY TUFF GONG AND UME RELEASE BOB MARLEY LIMITED-EDITION VINYL SERIES PRESSED AT TUFF GONG INTERNATIONAL IN JAMAICA - AVAILABLE MARCH 24

Retrieved on: 
星期五, 二月 3, 2023
Elysian, Aurora, Life, Music, Design director, Easy Skanking in Boston '78, Sirius XM, ICON, Bob Marley and the Wailers, Ziggy, Friends, Bob Marley Museum, Family, Fashion icon, MOG, Golden Joystick Awards, Creative director, Island Records, HERE, Aurora James, Creative, Ovation Hollywood, Stir It Up, Love, YOUTUBE, Universal Music Enterprises, Entertainment, Film industry, Khalia, Jamaican, Tuff Gong, Legend, Sound

Produced entirely by Bob Marley & the Wailers and mixed by longtime Marley associate Errol Brown, this Jamaican version are now on vinyl for the first time.

Key Points: 
  • Produced entirely by Bob Marley & the Wailers and mixed by longtime Marley associate Errol Brown, this Jamaican version are now on vinyl for the first time.
  • "Fashion Icon," the tenth episode of the Webby-award-winning,* 12-part documentary series Legacy, premieres today on Bob Marley's Official YouTube Channel.
  • Join the Bob Marley 78th birthday celebrations LIVE on Monday, February 6, 2023, on the Tuff Gong TV YouTube channel .
  • To watch the live stream or for more information on all Bob Marley birthday festivities, please click HERE

The Sumaira Foundation Announces Acquisition of the Connor B. Judge Foundation

Retrieved on: 
星期四, 八月 4, 2022
MOGAD, Vomiting, Neuromyelitis optica spectrum disorder, CNS, Common, Leadership, Connor, Paraplegia, Research, TSF, Caregiver, Cleveland Clinic, Foundation, Patient, NMO, Academic health science centre, Cell, Shake it Up Australia Foundation, Color, Family, Education, MOG, Severe cognitive impairment, Central nervous system, Spasticity, Awareness, Hiccup, Degenerative disease, Seizure, Cleveland, Weakness, Hypoesthesia, NMOSD, Immune system, Paralysis, Organization, Pharmaceutical industry, Management, Medicine

Judge Foundation (CBJF), a nonprofit started in 2014 to raise awareness and support research for NMOSD and other related autoimmune disorders.

Key Points: 
  • Judge Foundation (CBJF), a nonprofit started in 2014 to raise awareness and support research for NMOSD and other related autoimmune disorders.
  • The Sumaira Foundation is a 501(c)(3) organization dedicated to generating global awareness of neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
  • The Foundation also works to foster real connections between people affected by NMOSD and MOGAD through its international Ambassador Program.
  • Judge Foundation (CBJF), a family-based nonprofit with a mission to raise awareness and fund research for NMOSD and other severe autoimmune diseases.

ProSomnus® Presents Data Validating Proprietary FDA-cleared Oral Appliance Therapy Devices at 2022 American Academy of Dental Sleep Medicine Annual Meeting

Retrieved on: 
星期五, 五月 13, 2022
American Academy, Somnolence, Annual general meeting, Obstructive sleep apnea, Snoring, 2021 Essex County Council election, Patient, Poster, Digital Archives, Choking, Stroke, Continuous positive airway pressure, Â, SAN, Computer-aided design, AHI, Compliance, Heart failure, MOG, Jaw, REI, CPAP, H1, Entrepreneurship, GLOBE, MIP, MD, Hypertension, Sleep, Pharmaceutical industry, Health insurance

ProSomnus presented the data in three poster presentations at the 2022 American Academy of Dental Sleep Medicine (AADSM) Annual Meeting, held from May 13-15 in Dallas, Texas.

Key Points: 
  • ProSomnus presented the data in three poster presentations at the 2022 American Academy of Dental Sleep Medicine (AADSM) Annual Meeting, held from May 13-15 in Dallas, Texas.
  • These data presented at AADSM validate ProSomnuss oral appliance therapy devices in mild and moderate obstructive sleep apnea and, in particular, show great promise among patients with severe obstructive sleep apnea, said John E. Remmers, MD, Chief Scientist of ProSomnus.
  • The presented abstracts validating ProSomnuss oral appliance therapy devices include:
    An evaluation of data from two studies found ProSomnuss oral appliance therapy effective with most severe obstructive sleep apnea patients, suggesting that oral appliance therapy could be a suitable alternative to CPAP, especially when generated from digital intraoral scans using computer-aided design and manufacturing.
  • With more than 150,000 patients treated, ProSomnuss devices are the most prescribed oral appliance therapy in the U.S. To learn more, visit www.ProSomnus.com .

DGAP-News: Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of ImotopeTM IMCY-0141 for Multiple Sclerosis

Retrieved on: 
星期三, 四月 13, 2022
Protein, RRMS, Clinical trial, Paralysis, Catholic higher education, Wallonia, Multiple sclerosis, Woman, Population, Adult, Peptide, Research, MOG, Muscle weakness, University of Lille, Central nervous system, Patient, Tremor, Spasm, Autoimmune disease, Heredity, Technology, Split of the Catholic University of Leuven, Man, Degenerative disease, Safety, Biology, Disease, University, MS, Health, Attack, CD4, Pharmaceutical industry, Vaccine

"The dosing of the first patient in this study is an important milestone for Imcyse, as we advance our second ImotopeTM into the clinic.

Key Points: 
  • "The dosing of the first patient in this study is an important milestone for Imcyse, as we advance our second ImotopeTM into the clinic.
  • The IMCY-MS-001 Phase 1/2 trial will evaluate IMCY-0141 in adult patients with RRMS.
  • The Phase 2 expansion arm of the trial will be double-blind, randomized, and placebo controlled with an adaptive design.
  • Beyond type 1 diabetes and MS, Imcyse is developing a pipeline of ImotopesTM for the treatment of several autoimmune diseases.

Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of Imotope™ IMCY-0141 for Multiple Sclerosis

Retrieved on: 
星期三, 四月 13, 2022
Protein, RRMS, Clinical trial, Paralysis, Catholic higher education, Wallonia, Multiple sclerosis, Woman, Population, Adult, Peptide, Research, MOG, Muscle weakness, University of Lille, Central nervous system, GLOBE, Patient, Tremor, Spasm, Autoimmune disease, Heredity, Technology, Split of the Catholic University of Leuven, Man, Degenerative disease, Safety, Biology, Disease, University, MS, Health, Attack, CD4, Pharmaceutical industry, Vaccine

The dosing of the first patient in this study is an important milestone for Imcyse, as we advance our second Imotope into the clinic.

Key Points: 
  • The dosing of the first patient in this study is an important milestone for Imcyse, as we advance our second Imotope into the clinic.
  • The IMCY-MS-001 Phase 1/2 trial will evaluate IMCY-0141 in adult patients with RRMS.
  • The Phase 2 expansion arm of the trial will be double-blind, randomized, and placebo controlled with an adaptive design.
  • Beyond type 1 diabetes and MS, Imcyse is developing a pipeline of Imotopes for the treatment of several autoimmune diseases.

iQIYI Upgrades Collaboration Model for Online Film Distribution

Retrieved on: 
星期五, 四月 1, 2022
Cloud, Risk, Teddy Chan, Classification, IQIYI, Growth, MOG, Direct, CNNIC, China Internet Network Information Center, PVOD, Lead, RMB, Industry, Dream, Ecosystem, Time, Subscription business model, SVOD, Attention, DTC, Video game

BEIJING, April 1, 2022 /PRNewswire/ -- iQIYI, an innovative market-leading online entertainment service in China, announced on Apr.1 that it will upgrade its collaboration model for online film distribution starting today. The new model includes two distribution models, Cloud Cinema Premiere and Subscription Premiere. Films released under the Cloud Cinema Premiere model will generate revenues from both the Premium Video on Demand (PVOD) and Subscription Video on Demand (SVOD) models of streaming. Meanwhile, for films released under the Subscription Premiere model, the revenue shared with film producers will be determined by users' viewing time alone, rather than according to the different fee category classifications iQIYI had assigned to individual films.

Key Points: 
  • BEIJING, April 1, 2022 /PRNewswire/ -- iQIYI, an innovative market-leading online entertainment service in China, announced on Apr.1 that it will upgrade its collaboration model for online film distribution starting today.
  • The new collaboration model launched by iQIYI represents a complete shift from film classifications, a move designed to ensure equal distribution support for all films before their premiere.
  • The upgraded model helps initiate a Direct-to-Consumer (DTC) model in China's film and television industry.
  • iQIYI took the lead among Chinese video streaming platforms in exploring the PVOD model by introducing a new avenue for film distribution for the entire industry.